Complement factor H is expressed in adipose tissue in association with insulin resistance

Diabetes

Volumn 59, Issue 1, 2010, Pages 200-209

  Moreno Navarrete, José María ^a   Martínez Barricarte, Rubén ^b   Catalán, Victoria ^c,d   Sabater, Mònica ^a   Gómez Ambrosi, Javier ^c,d   Ortega, Francisco José ^a   Ricart, Wifredo ^a   Blüher, Mathias ^e   Frühbeck, Gema ^c,d   De Cordoba, Santiago Rodríguez ^b   Fernández Real, José Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT FACTOR H; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; COMPLEMENT FACTOR H, HUMAN;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; ANTIBODY SPECIFICITY; CAUCASIAN; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE TOLERANCE TEST; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OMENTUM; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; SKIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; COMPLEMENT FACTOR B; COMPLEMENT FACTOR H; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; OBESITY; OMENTUM; ORGAN SPECIFICITY; REFERENCE VALUES; SKIN; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 77449136807     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0700     Document Type: Article

References (47)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867
2. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783
3. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-2180
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808
5. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-1248
6. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47
7. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397
8. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301
9. Walport MJ. Complement: first of two parts. N Engl J Med 2001;344:1058-1066
10. Walport MJ. Complement: second of two parts. N Engl J Med 2001;344:1140-1144
11. Sjöberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009;30:83-90
12. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007;171:715-727
13. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nat Rev Immunol 2008;8:48-58
14. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41:355-367
15. de Córdoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151:1-13
16. Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol 2009;46:1573-1594
17. Paglialunga S, Fisette A, Yan Y, Deshaies Y, Brouillette JF, Pekna M, Cianflone K. Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice. Am J Physiol Endocrinol Metab 2008;294:E521-E529
18. Xia Z, Cianflone K. Acylation-stimulating protein precursor proteins in adipose tissue in human obesity. Metabolism 2003;52:1360-1366
19. Gabrielsson BG, Johansson JM, Lönn M, Jernås M, Olbers T, Peltonen M, Larsson I, Lönn L, Sjö ström L, Carlsson B, Carlsson LM. High expression of complement components in omental adipose tissue in obese men. Obes Res 2003;11:699-708
20. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267:12736-12741
21. Peake PW, O'Grady S, Pussell BA, Charlesworth JA. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest 1997;27:922-927
22. Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, Cianflone K. C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 2005;280:23936-23944
23. Xia Z, Stanhope KL, Digitale E, Simion OM, Chen L, Havel P, Cianflone K. Acylation-stimulating protein (ASP)/complement C3adesArg deficiency results in increased energy expenditure in mice. J Biol Chem 2004;279:4051-4057
24. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003;1609:127-143
25. Schrauwen P, Hesselink MK, Jain M, Cianflone K. Acylation-stimulating protein: effect of acute exercise and endurance training. Int J Obes (Lond) 2005;29:632-638
26. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000;23:779-785
27. Muscari A, Antonelli S, Bianchi G, Cavrini G, Dapporto S, Ligabue A, Ludovico C, Magalotti D, Poggiopollini G, Zoli M, Pianoro Study Group. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 2007;30:2362-2368
28. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes (Lond) 2005;29:429-435
29. Somani R, Grant PJ, Kain K, Catto AJ, Carter AM. Complement C3 and C-reactive protein are elevated in South Asians independent of a family history of stroke. Stroke 2006;37:2001-2006
30. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycaemic glucose clamp. J Clin Invest 1987;79:790-800
31. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63
32. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410
33. Sánchez-Corral P, Pérez-Caballero D, Huarte O, Simckes AM, Goicoechea E, López-Trascasa M, de Córdoba SR. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002;71:1285-1295
34. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007;104:240-245
35. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997;107:1-7
36. Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis JE, Damm D, White T, Spiegelman BM. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 1989;244:1483-1487
37. Choy LN, Spiegelman BM. Regulation of alternative pathway activation and C3a production by adipose cells. Obes Res 1996;4:521-532
38. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749
39. Sniderman AD, Cianflone K. The adipsin-ASP pathway and regulation of adipocyte function. Ann Med 1994;26:388-393
40. Atkinson JP, Goodship TH. Complement factor H and the hemolytic uremic syndrome. J Exp Med 2007;204:1245-1248
41. Zipfel PF, Heinen S, Józsi M, Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006;43:97-106
42. Levy Y, George J, Yona E, Shoenfeld Y. Partial lipodystrophy, mesangio-capillary glomerulonephritis and complement dysregulation: an autoimmune phenomenon. Immunol Res 1998;18:55-60
43. Mathieson PW, Peters DK. Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system. Nephrol Dial Transplant 1997;12:1804-1806
44. Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immunol 1995;13:277-305
45. Heumann D. CD14 and LBP in endotoxemia and infections caused by Gram-negative bacteria. J Endotoxin Res 2001;7:439-441
46. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-1481
47. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772